决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Cancer stem cell mechanisms and targeted therapeutic strategies in head and neck squamous cell carcinoma.
头颈部鳞状细胞癌(HNSCC)起源于口腔、咽和喉的上皮衬里,2020 年全球新诊断病例超过 830,000 例,是第七大常见癌症。
头颈部鳞状细胞癌(HNSCC)起源于口腔、咽部和喉部的上皮内衬;2020年全球新诊断病例超过83万例,是第七大常见癌症。尽管治疗有所进步,高级别HNSCC的结局仍不佳且复发风险高。虽然癌症干细胞(CSC)在HNSCC肿瘤中较少见,却是肿瘤复发的重要驱动因素;它们通过增强DNA修复和维持静息状态逃避细胞凋亡、抵抗现行治疗。本综述整合近期发现,建立理解CSC机制的统一框架。文章考察多能性因子、生物标志物、复制性永生化、代谢重编程、氧化还原调控和免疫逃逸如何塑造CSC行为及其在治疗压力下的存活。还讨论非编码RNA如何通过表观遗传调节影响CSC基因表达。重要的是,本文指出这些适应机制相互交织,可形成潜在脆弱点,通过同时靶向多条通路来清除CSC。最后,本文介绍近期和新兴精准疗法,包括CAR-T细胞、免疫检查点抑制剂、代谢及氧化还原靶向药物和表观遗传调节剂;这些方法正应用于临床前及临床试验,旨在清除CSC并改善HNSCC患者结局。
Head and neck squamous cell carcinoma (HNSCC) originates in the epithelial lining of the oral cavity, pharynx, and larynx, with over 830,000 new cases diagnosed globally in 2020, making it the seventh most prevalent cancer. Despite treatment advances, high-grade HNSCCs remain associated with poor outcomes and a high risk of recurrence. Although Cancer Stem Cells (CSCs) are rare in HNSCC tumors, they are key drivers of tumor relapses, as they evade apoptosis and survive current therapies through enhanced DNA repair and quiescence. This review integrates recent discoveries into a unified framework for understanding CSC mechanisms. It examines the role of pluripotency factors, biomarkers, replicative immortalization, metabolic reprogramming, redox regulation, and immune evasion in shaping CSC behavior and survival under treatment stress. Non-coding RNAs are also discussed as modulators of gene expression via epigenetic regulation in CSCs. Importantly, it highlights how these adaptive mechanisms intersect as potential vulnerabilities that could be exploited to eliminate CSCs through targeting multiple pathways. Finally, it provides recent and emerging precision therapeutics, including CAR-T cells, immune checkpoint inhibitors, metabolic and redox-targeting agents, and epigenetic modulators currently in preclinical and clinical trials applications designed to eliminate CSCs and improve patient outcomes in HNSCC.
MEMBER ACCOUNT
登录成功会直接打开下一页。